THU0392 Do we really need dmards addition to ankylosisng spondylitis patients treated with tumor necrosis factor alpha inhibitors?
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.2584
Abstract: Background The management of systemic inflammatory diseases, such as Rheumatoid arthritis (RA) and Ankylosing spondylitis (AS) has been revolutionized with the introduction of tumor necrosis factor alpha inhibitors (TNF-I). Significant reduction in disease activity and… read more here.
Keywords: patients treated; haca; factor alpha; tumor necrosis ... See more keywords